Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Oct 8;20(1):126–135. doi: 10.1016/j.cgh.2020.10.003

Figure 3.

Figure 3.

Comparative effectiveness of vedolizumab vs TNF antagonist therapy in UC for achieving clinical remission and deep remission. (A) Comparative effectiveness of vedolizumab vs TNF antagonist therapy for clinical remission. (B) Comparative effectiveness of vedolizumab vs TNF antagonist therapy for deep remission (clinical + endoscopic remission). CI, confidence interval; IPW, inverse probability weighting; TNF antagonist, tumor necrosis factor antagonist (infliximab, adalimumab, golimumab); UC, ulcerative colitis. Deep remission was defined as achieving clinical remission (resolution of diarrhea, rectal bleeding, and/or urgency) and endoscopic remission (Mayo endoscopic subscore 0 or 1).